Keros Therapeutics Inc. (KROS)
Market Closed
3 Jun, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
10. 50
-0.05
-0.4739%
Pre Market
$
+1.06 +10.0952% 11. 56
361.9M Market Cap
- P/E Ratio
- Div Yield
189,387 Volume
-5.27 Eps
$ 10.55
Previous Close 
Want to track KROS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers
Five Keros Therapeutics, Inc. abstracts are expected at the upcoming EHA conference between June 13th -16th of 2024, showcasing data using KER-050 for the treatment of patients with low-risk myelodysplastic syndrome. The company has already met with the FDA and agreed on a design for a phase 3 study using KER-050 for the treatment of low-risk MDS. The global myelodysplastic syndrome market is projected to reach $6.10 billion by 2029.
Seekingalpha | 1 year ago
